US FDA clears Jubilant Therapeutics’ IND for novel dual LSD1 & HDAC6 inhibitor, JBI-802 for treatment of solid tumours
Synopsis: Jubilant Therapeutics Inc, a biopharmaceutical company, announced US Food and Drug Administration (FDA) clearance of the investigational new drug application (IND)…